An International Publisher for Academic and Scientific Journals
Author Login 
Scholars Journal of Applied Medical Sciences | Volume-6 | Issue-04
Study of Use of Single Dose of Oral Mifepristone in Induction of Labour
Dr. Purva Reelkar, Dr. Anita Solunke, Dr. Gautam Aher, Dr. Mrs. Urmila Shinde
Published: April 30, 2018 | 138 158
DOI: 10.36347/sjams.2018.v06i04.085
Pages: 1796-1800
Downloads
Abstract
Mifepristone is a steroidal compound that has antiglucocorticoid and antiprogesterone properties. It increases uterine activity, causes cervical effacement and dilatation, needed for the delivery. The objectives of this study were to know the efficacy of single dose of oral mifepristone in third trimester cervical ripening for induction of labour and to know the side-effects of oral mifepristone. Sample size of 100 was divided into two groups of 50 each, cases and control. Pre induction Bishop’s score was evaluated. 50 patients in the cases group were given a single dose of tablet mifepristone 200 mg orally and were reviewed after 24 hours for cervical changes and Bishop’s score was calculated. Control group was not given any drug. Final outcome was evaluated. It was found that in the cases group, 32 patients had preinduction Bishop’s score of <4, 14 patients had a score between 4 to 7 and 4 patients had a score of >7. The corresponding values in the control group were, 24, 19 and 07, respectively. Postinduction calculation of Bishop’s score revealed that, in the cases group, 17 patients had a score of <4, 21 patients had a score between 4 to 7 and 12 patients had a score of >7, whereas in the control group, the corresponding number of patients in each group were 22, 20 and 8, respectively. The mean induction-delivery interval was 33 hours in the cases group and 41 hours in the control group. 15 patients out of 50 in the cases group and 27 patients out of 50 in the control group needed additional induction for the delivery. Mifepristone is an effective induction agent for cervical ripening and initiation of labor when given 24 hours prior with reduced need for prostaglandins and can be administered safely with no increase in adverse effects on the fetus or mother.